Crystallographic and Selectivity Studies on the Approved HIF Prolyl Hydroxylase Inhibitors Desidustat and Enarodustat

Documenti analoghi

• Modulation of Tau Protein Neurotoxic Hallmarks by Novel σ 1 R Agonists/HDAC Inhibitor Dual‐Acting Compounds
  di: Antonino N. Fallica, et al.
  Pubblicazione: (2026)
• Key Insights on the Classification and Theranostic Applications of Magnetic Resonance Imaging Contrast Agents
  di: Jasleen Kaur, et al.
  Pubblicazione: (2024)
• Design, Synthesis, and Biological Evaluation of Novel Triazine‐Based Dual Histone Deacetylase/phosphatidylinositol 3‐kinase Inhibitors for Breast Cancer Therapy
  di: Lara Luzietti, et al.
  Pubblicazione: (2026)
• APH Inhibitors that Reverse Aminoglycoside Resistance in Enterococcus casseliflavus
  di: Elise Kaplan, et al.
  Pubblicazione: (2025)
• The Role of Protein Disulfide Isomerase Inhibitors in Cancer Therapy
  di: Qiuying Nie, et al.
  Pubblicazione: (2024)